Clinical Trials Browser

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT05279677 2022-08-23

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Phase 2 Unknown

30 enrolled

Gastrointestinal

Colonic Neoplasms

NCT04116775 2022-06-23

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Phase 2 Unknown

32 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT05001360 2021-10-27

Study of FMT Combined With Nivolumab in Gastric Cancer

Phase NA Withdrawn

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT04264975 2020-02-17

Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology

Phase NA Unknown

60 enrolled

Solid Carcinoma

NCT04056026 2019-09-23

A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma

Phase EARLY_PHASE1 Completed

1 enrolled

Other solid neoplasmThoracic

Mesothelioma

NCT03353402 2019-04-03

Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy

Phase 1 Unknown

40 enrolled

Dermatologic

Melanoma

NCT02433483 2017-11-01

Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients

Phase 2 Terminated

4 enrolled 11 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Clinical Trials

FMT-CACH

Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

FMT-LUNG

Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

FRIDA

NIVO-FMT

Immunobiome

PERFORM

FLORA

MITRIC

Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer

FMT-TP

FMT-NENs

Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection

Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy

FMT to Convert Response to Immunotherapy

Washed Microbiota Transplantation for the Treatment of Oncotherapy-Related Intestinal Complications

FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer

FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC

Fecal Microbiota Transplant (FMT) in Melanoma Patients

Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1

FMT-LUMINATE

A Study of FMT in Patients With AML Allo HSCT in Recipients

FEMITGIGVHD

Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer

TMF-Allo